CSL's new chief executive pick gets mixed reviews from Macquarie
Macquarie is split on CSL's choice of Deborah Waterhouse as CEO, citing her lack of plasma and rare-disease experience. Shares are down 0.2% at A$195.64.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Macquarie has mixed views on CSL's selection of Deborah Waterhouse as chief executive, according to Market Talk, which cites a note from the bank's analysts. They believe she could help sustain the Australian drugmaker's commercial momentum.
However, the analysts point out that Waterhouse has no experience with plasma or rare diseases, while CSL's core businesses span a broad range of therapies and markets. She has also never held a role facing public markets and will be based in the U.K., far from CSL's main manufacturing sites and largest markets.
Macquarie rates the stock neutral with a target price of A$174.00. The shares are down 0.2% at A$195.64.
why it matters
A leadership change at a large drugmaker matters to investors because it shapes expectations for growth and strategy. The bank's view suggests the market will watch closely how the new CEO handles operations and communication with investors. The note reflects the opinion of a single brokerage and does not forecast the share price.
market impact
CSL and ASX healthcare: CEO change adds uncertainty to the company's valuation
tags
instruments
sources
- CSL's CEO Pick Has Pros and Cons for Macquarie — Market Talk, 22 October 2026 at 02:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗